Postauthorization safety study of Clottafact® , a triply secured fibrinogen concentrate in acquired fibrinogen deficiency: a prospective observational study.
C NégrierA-S Ducloy-BouthorsV PiriouE De MaistreN StieltjesA Borel-DerlonPascal H ColsonJ PicardT LambertS ClaeyssensS BoileauA BertrandM-H AndréF FourrierY OzierP SiéY GruelZ TellierPublished in: Vox sanguinis (2017)
The Clottafact® safety profile observed during the study matched the known profile of fibrinogen during use.
Keyphrases